Compare HWBK & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HWBK | BDSX |
|---|---|---|
| Founded | 1865 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.4M | 62.5M |
| IPO Year | N/A | 2020 |
| Metric | HWBK | BDSX |
|---|---|---|
| Price | $32.57 | $6.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 10.9K | ★ 66.8K |
| Earning Date | 01-21-2026 | 11-03-2025 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | ★ 259.86 | N/A |
| EPS | ★ 3.19 | N/A |
| Revenue | $77,904,000.00 | ★ $80,173,000.00 |
| Revenue This Year | N/A | $20.75 |
| Revenue Next Year | N/A | $25.05 |
| P/E Ratio | $10.10 | ★ N/A |
| Revenue Growth | ★ 45.83 | 22.29 |
| 52 Week Low | $25.21 | $3.44 |
| 52 Week High | $36.49 | $31.20 |
| Indicator | HWBK | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 42.44 |
| Support Level | $32.07 | $6.56 |
| Resistance Level | $33.05 | $7.03 |
| Average True Range (ATR) | 0.96 | 0.57 |
| MACD | -0.44 | -0.13 |
| Stochastic Oscillator | 11.84 | 25.24 |
Hawthorn Bancshares Inc is a financial holding company and along with its subsidiary, it conducts general banking and trust business, offering its customers checking and savings accounts, internet banking, certificates of deposit, trust services, brokerage services, and safety deposit boxes. The company also offers a range of lending services, including commercial and industrial loans, single payment personal loans, installment loans, and commercial and residential real estate loans.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.